Abstract

REVIEW OF CLINICAL USE OF MONOCLONAL ANTIBODIES (BEVACIZUMAB)

Novia Fahrina Purnama Sari*, Made Dwike Swari Santi, Cece Furwanti, Anggara Martha Pratama and Farida Ulfa

.

Abstract

Bevacizumab is a humanized monoclonal antibody that has several potentials as a single agent or in combination with a chemotherapeutic agent. The first used in metastatic colorectal cancer (mCRC) therapy, metastatic breast cancer (mBC) therapy, and non-small cell lung cancer (NSCLC) therapy. Furthermore, there is evidence of clinical use for antiangiogenic therapy, as assessed by endothelial cell proliferation and tubule formation and widely accepted as first-line therapy in combination with chemotherapy. Due to the clinical validation of bevacizumab as a specific inhibitor of the interaction between VEGFA and VEGFR2, the increasing number of monoclonal antibodies in development has targeted VEGFR2 as a promising molecular target for anti-angiogenesis.

Keywords: Bevacizumab, monoclonal antibodies, VEGF-A, VEGFR2, and angiogenesis.